Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MONRO, INC.MNRO · Entity 5682 | Director | August 11, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MONRO, INC.
Report date August 11, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,077 |
Reported balance
After 2026-08-11 transaction · row 1
1 source rowRow 1 · 2026-08-11 · Grant · Acquired 11,149 · Balance 43,077 F1: This award of restricted stock is granted under the Company's Amended and Restated 2007 Stock Incentive Plan (the "Plan") and vests one-third on each of the three anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This award of restricted stock is granted under the Company's Amended and Restated 2007 Stock Incentive Plan (the "Plan") and vests one-third on each of the three anniversaries of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ImmunoGen, Inc.
Report date February 12, 2024 · Filed February 12, 2024
Section 16 reporting ended · disclosed 2024-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-12 · Disposition to issuer · Disposed 13,090 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). F2: At the effective time of the Merger (the "Effective Time"), each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer ("Common Stock") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) $31.26, without interest (the "Merger Consideration"). |
| Deferred Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-12 · Disposition to issuer · Disposed 105,458 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.10 · Expires 2024-11-11 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.07 · Expires 2025-11-10 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.84 · Expires 2026-12-09 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-12 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 · Expires 2027-06-13 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-02-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.21 · Expires 2028-06-20 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-02-12 · Disposition to issuer · Disposed 18,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.10 · Expires 2029-06-20 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-02-12 · Disposition to issuer · Disposed 18,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.56 · Expires 2030-06-17 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-02-12 · Disposition to issuer · Disposed 50,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2031-06-16 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-02-12 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2032-06-15 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-02-12 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.72 · Expires 2033-06-14 | Direct | 0 |
Reported balance
After 2024-02-12 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-02-12 · Disposition to issuer · Disposed 19,597 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger").
F2: At the effective time of the Merger (the "Effective Time"), each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer ("Common Stock") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) $31.26, without interest (the "Merger Consideration").
F3: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2026 Filed Aug 12, 2026 19:23 UTC | MONRO, INC. MNRO · Entity 5682 | GrantCommon Stock | 11,149 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-346678 · ownership.xml · nonDerivative · entry 1 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,077 F1 · shares: This award of restricted stock is granted under the Company's Amended and Restated 2007 Stock Incentive Plan (the "Plan") and vests one-third on each of the three anniversaries of the grant date. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 17:37 UTC | MONRO, INC. MNRO · Entity 5682 | GrantRestricted Stock Award | 8,306 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-107826 · ownership.xml · nonDerivative · entry 1 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,928 F1 · shares: This award of restricted stock is granted under the Company's Amended and Restated 2007 Stock Incentive Plan (the "Plan") and vests one-third on each of the three anniversaries of the grant date. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 19:46 UTC | MONRO, INC. MNRO · Entity 5682 | GrantRestricted Stock Award | 4,937 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-097535 · ownership.xml · nonDerivative · entry 1 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,622 F1 · shares: This award of restricted stock is granted under the Company's Amended and Restated 2007 Stock Incentive Plan (the "Plan") and vests one-third on each of the three anniversaries of the grant date. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:40 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 19,597 | Not disclosed Strike: $17.72 | Not disclosed |
DisclosureSEC source: 0001104659-24-014704 · tm245865-6_4seq1.xml · derivative · entry 12 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,597 shares Expires 2033-06-14 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:40 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 44,000 | Not disclosed Strike: $3.37 | Not disclosed |
DisclosureSEC source: 0001104659-24-014704 · tm245865-6_4seq1.xml · derivative · entry 11 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,000 shares Expires 2032-06-15 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:40 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 44,000 | Not disclosed Strike: $6.77 | Not disclosed |
DisclosureSEC source: 0001104659-24-014704 · tm245865-6_4seq1.xml · derivative · entry 10 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,000 shares Expires 2031-06-16 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:40 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $4.56 | Not disclosed |
DisclosureSEC source: 0001104659-24-014704 · tm245865-6_4seq1.xml · derivative · entry 9 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2030-06-17 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:40 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,000 | Not disclosed Strike: $2.10 | Not disclosed |
DisclosureSEC source: 0001104659-24-014704 · tm245865-6_4seq1.xml · derivative · entry 8 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2029-06-20 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:40 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,000 | Not disclosed Strike: $11.21 | Not disclosed |
DisclosureSEC source: 0001104659-24-014704 · tm245865-6_4seq1.xml · derivative · entry 7 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2028-06-20 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:40 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $4.64 | Not disclosed |
DisclosureSEC source: 0001104659-24-014704 · tm245865-6_4seq1.xml · derivative · entry 6 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-06-13 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:40 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,000 | Not disclosed Strike: $1.84 | Not disclosed |
DisclosureSEC source: 0001104659-24-014704 · tm245865-6_4seq1.xml · derivative · entry 5 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2026-12-09 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:40 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $13.07 | Not disclosed |
DisclosureSEC source: 0001104659-24-014704 · tm245865-6_4seq1.xml · derivative · entry 4 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-11-10 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:40 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $10.10 | Not disclosed |
DisclosureSEC source: 0001104659-24-014704 · tm245865-6_4seq1.xml · derivative · entry 3 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-11-11 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:40 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerDeferred Share Unit · Derivative | 105,458 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001104659-24-014704 · tm245865-6_4seq1.xml · derivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,458 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 16:40 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Disposition to issuerRestricted Stock Unit · Derivative | 13,090 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001104659-24-014704 · tm245865-6_4seq1.xml · derivative · entry 1 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,090 shares Expires not disclosed F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). F2 · derivative.exercise_price: At the effective time of the Merger (the "Effective Time"), each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer ("Common Stock") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) $31.26, without interest (the "Merger Consideration"). F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). F2 · kind: At the effective time of the Merger (the "Effective Time"), each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer ("Common Stock") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) $31.26, without interest (the "Merger Consideration"). F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). F2 · price: At the effective time of the Merger (the "Effective Time"), each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer ("Common Stock") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) $31.26, without interest (the "Merger Consideration"). F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). F2 · derivative.exercise_date: At the effective time of the Merger (the "Effective Time"), each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer ("Common Stock") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) $31.26, without interest (the "Merger Consideration"). F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). F2 · derivative.expiration_date: At the effective time of the Merger (the "Effective Time"), each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer ("Common Stock") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) $31.26, without interest (the "Merger Consideration"). Read SEC document |
| September 13, 2023 Filed Sep 14, 2023 17:30 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $14.70 | $0.00 |
DisclosureSEC source: 0001415889-23-013291 · form4-09142023_090923.xml · derivative · entry 3 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2023-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on June 14, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · derivative.exercise_date: This option was granted on 11/12/2013 and is fully vested as of the transaction date. Read SEC document |
| September 13, 2023 Filed Sep 14, 2023 17:30 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Exercise / conversionCommon Stock | 10,000 | $16.05 | $160,500.00 |
DisclosureSEC source: 0001415889-23-013291 · form4-09142023_090923.xml · nonDerivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on June 14, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.90 to $16.10, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges. Read SEC document |
| September 13, 2023 Filed Sep 14, 2023 17:30 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | Exercise / conversionCommon Stock | 10,000 | $14.70 | $147,000.00 |
DisclosureSEC source: 0001415889-23-013291 · form4-09142023_090923.xml · nonDerivative · entry 1 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on June 14, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 12:22 UTC | MONRO, INC. MNRO · Entity 5682 | GrantRestricted Stock Awards | 3,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046178 · doc4.xml · nonDerivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,685 Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 16:48 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (right to buy) · Derivative | 19,597 | $0.00 Strike: $17.72 | $0.00 |
DisclosureSEC source: 0001415889-23-009951 · form4-06162023_080628.xml · derivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,597 Underlying: Common Stock · 19,597 shares Expires 2033-06-14 F3 · derivative.exercise_price: The stock options were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. F4 · derivative.exercise_date: The stock options vest ratably on each of 9/1/23, 12/1/23, 3/1/24, and 6/1/24, contingent upon the individual remaining a director as of each vesting date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 16:48 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantRestricted Stock Unit · Derivative | 13,090 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009951 · form4-06162023_080628.xml · derivative · entry 1 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,090 Underlying: Common Stock · 13,090 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units ("RSUs") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F1 · price: The restricted stock units ("RSUs") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date. F2 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 17:55 UTC | MONRO, INC. MNRO · Entity 5682 | GrantRestricted Stock Awards | 2,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046562 · doc4.xml · nonDerivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,936 Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:16 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (right to buy) · Derivative | 44,000 | $3.37 Strike: $3.37 | $148,280.00 |
DisclosureSEC source: 0001415889-22-006727 · form4-06172022_010645.xml · derivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2032-06-15 F4 · derivative.exercise_date: Exercisable as to 11,000 shares on each of 9/1/22, 12/1/22, 3/1/23, and 6/1/23, contingent upon the individual remaining a director as of each vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:16 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantDeferred Share Unit · Derivative | 15,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-006727 · form4-06172022_010645.xml · derivative · entry 1 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,458 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F2 · derivative.exercise_date: The deferred share units vest ratably over a one-year period in quarterly increments beginning on 9/1/22, contingent upon the individual remaining a director as of each vesting date. F3 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F3 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 18:40 UTC | MONRO, INC. MNRO · Entity 5682 | GrantRestricted Stock Award | 2,351 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-052487 · doc4.xml · nonDerivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,510 Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 20:25 UTC | MONRO, INC. MNRO · Entity 5682 | Exercise / conversionOptions (Right to Buy) · Derivative | 10,000 | $57.78 Strike: $57.78 | $577,800.00 |
DisclosureSEC source: 0001209191-21-050609 · doc4.xml · derivative · entry 4 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2021-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 20:25 UTC | MONRO, INC. MNRO · Entity 5682 | SaleCommon Stock | 10,000 | $58.65 | $586,528.00 |
DisclosureSEC source: 0001209191-21-050609 · doc4.xml · nonDerivative · entry 3 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,159 Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 20:25 UTC | MONRO, INC. MNRO · Entity 5682 | Exercise / conversionCommon Stock | 10,000 | $57.78 | $577,800.00 |
DisclosureSEC source: 0001209191-21-050609 · doc4.xml · nonDerivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 16:25 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (right to buy) · Derivative | 44,000 | $6.77 Strike: $6.77 | $297,880.00 |
DisclosureSEC source: 0001179110-21-006819 · edgar.xml · derivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2031-06-16 F4 · derivative.exercise_date: Exercisable as to 11,000 shares on each of 9/1/21, 12/1/21, 3/1/22, and 6/1/22, contingent upon the individual remaining a director as of each vesting date. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 16:25 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantDeferred Share Unit · Derivative | 15,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-006819 · edgar.xml · derivative · entry 1 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,458 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest quarterly on each of 9/1/21, 12/1/21, 3/1/22, and 6/1/22, contingent upon the individual remaining a director as of each vesting date. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 15:37 UTC | MONRO, INC. MNRO · Entity 5682 | GrantRestricted Stock Awards | 2,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-047684 · doc4.xml · nonDerivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,159 Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 16:08 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (right to buy) · Derivative | 50,000 | $4.56 Strike: $4.56 | $228,000.00 |
DisclosureSEC source: 0001179110-20-007532 · edgar.xml · derivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-06-17 F4 · derivative.exercise_date: Exercisable as to 12,500 shares on each of 9/1/20, 12/1/20, 3/1/21 and 6/1/21, contingent upon the individual remaining a director as of each vesting date. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 16:08 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantDeferred Share Unit · Derivative | 17,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007532 · edgar.xml · derivative · entry 1 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,458 Underlying: Common Stock · 17,000 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest quarterly on each of 9/1/20, 12/1/20, 3/1/21 and 6/1/21, contingent upon the individual remaining a director as of each vesting date. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 16:11 UTC | MONRO, INC. MNRO · Entity 5682 | GrantRestricted Stock Awards | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-046047 · doc4.xml · nonDerivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,584 Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 10:25 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (right to buy) · Derivative | 18,000 | $2.10 Strike: $2.10 | $37,800.00 |
DisclosureSEC source: 0001179110-19-008043 · edgar.xml · derivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2029-06-20 F4 · derivative.exercise_date: Exercisable as to 4,500 shares on 9/1/19, 12/1/19, 3/1/20 and 6/1/20, contingent upon the individual remaining a director as of each vesting date. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 10:25 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantDeferred Share Unit · Derivative | 4,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-008043 · edgar.xml · derivative · entry 1 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,458 Underlying: Common Stock · 4,000 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest quarterly on 9/1/19, 12/1/19, 3/1/20 and 6/1/20, contingent upon the individual remaining a director as of each vesting date. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 17:28 UTC | MONRO, INC. MNRO · Entity 5682 | Exercise / conversionOptions (Right to Buy) · Derivative | 10,000 | $51.51 Strike: $51.51 | $515,100.00 |
DisclosureSEC source: 0001209191-19-010928 · doc4.xml · derivative · entry 7 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2019-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 17:28 UTC | MONRO, INC. MNRO · Entity 5682 | SaleCommon Stock | 100 | $80.34 | $8,033.80 |
DisclosureSEC source: 0001209191-19-010928 · doc4.xml · nonDerivative · entry 6 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,923 Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 17:28 UTC | MONRO, INC. MNRO · Entity 5682 | SaleCommon Stock | 2,000 | $78.68 | $157,361.20 |
DisclosureSEC source: 0001209191-19-010928 · doc4.xml · nonDerivative · entry 5 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,023 F3 · price: The price reported is a weighted average price. these shares were sold in multiple transactions at prices ranging from $78.26 to $78.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 17:28 UTC | MONRO, INC. MNRO · Entity 5682 | SaleCommon Stock | 4,600 | $77.70 | $357,432.42 |
DisclosureSEC source: 0001209191-19-010928 · doc4.xml · nonDerivative · entry 4 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,023 F2 · price: The price reported is a weighted average price. these shares were sold in multiple transactions at prices ranging from $77.28 to $78.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 17:28 UTC | MONRO, INC. MNRO · Entity 5682 | SaleCommon Stock | 3,300 | $76.76 | $253,309.98 |
DisclosureSEC source: 0001209191-19-010928 · doc4.xml · nonDerivative · entry 3 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,623 F1 · price: The price reported is a weighted average price. these shares were sold in multiple transactions at prices ranging from $76.25 to $77.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 17:28 UTC | MONRO, INC. MNRO · Entity 5682 | Exercise / conversionCommon Stock | 10,000 | $51.51 | $515,100.00 |
DisclosureSEC source: 0001209191-19-010928 · doc4.xml · nonDerivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 17:57 UTC | MONRO, INC. MNRO · Entity 5682 | GrantRestricted Stock Award | 1,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-046966 · doc4.xml · nonDerivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,923 Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 14:07 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (right to buy) · Derivative | 18,000 | $11.21 Strike: $11.21 | $201,780.00 |
DisclosureSEC source: 0001179110-18-008933 · edgar.xml · derivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-06-20 F4 · derivative.exercise_date: Exercisable as to 4,500 shares on 9/1/18, 12/1/18, 3/1/19 and 6/1/19, contingent upon the individual remaining a director as of each vesting date. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 14:07 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantDeferred Share Unit · Derivative | 4,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008933 · edgar.xml · derivative · entry 1 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,458 Underlying: Common Stock · 4,000 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest quarterly on 9/1/18, 12/1/18, 3/1/19 and 6/1/19, contingent upon the individual remaining a director as of each vesting date. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document |
| February 05, 2018 Filed Feb 5, 2018 21:09 UTC | MONRO, INC. MNRO · Entity 5682 | Exercise / conversionOptions (Right to Buy) · Derivative | 10,000 | $44.46 Strike: $44.46 | $444,600.00 |
DisclosureSEC source: 0001209191-18-007428 · doc4.xml · derivative · entry 4 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2018-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2018 Filed Feb 5, 2018 21:09 UTC | MONRO, INC. MNRO · Entity 5682 | SaleCommon Stock | 10,000 | $55.51 | $555,100.00 |
DisclosureSEC source: 0001209191-18-007428 · doc4.xml · nonDerivative · entry 3 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,095 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold. F1 · balance_after: Includes 2,895 shares of restricted stock, originally granted on August 15, 2017, which vest according to the following schedule: (i) 965 shares vest on August 15, 2018, (ii) 965 shares vest on August 15, 2019, and (iii) the final 965 shares vest on August 15, 2020. Read SEC document |
| February 05, 2018 Filed Feb 5, 2018 21:09 UTC | MONRO, INC. MNRO · Entity 5682 | Exercise / conversionCommon Stock | 10,000 | $44.46 | $444,600.00 |
DisclosureSEC source: 0001209191-18-007428 · doc4.xml · nonDerivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,895 shares of restricted stock, originally granted on August 15, 2017, which vest according to the following schedule: (i) 965 shares vest on August 15, 2018, (ii) 965 shares vest on August 15, 2019, and (iii) the final 965 shares vest on August 15, 2020. Read SEC document |
| August 15, 2017 Filed Aug 16, 2017 19:22 UTC | MONRO, INC. MNRO · Entity 5682 | GrantRestricted Stock Awards | 2,895 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-020468 · doc4.xml · nonDerivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,095 Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 18:02 UTC | MONRO, INC. MNRO · Entity 5682 | PurchaseCommon Stock | 1,200 | $46.45 | $55,736.16 |
DisclosureSEC source: 0000899243-17-018957 · doc4.xml · nonDerivative · entry 2 MCCLUSKI STEPHEN C · CIK 0001188728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $46.35 to $46.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.